CLINICAL TRIALS PROFILE FOR COLISTIN SULFATE
✉ Email this page to a colleague
All Clinical Trials for COLISTIN SULFATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02472600 ↗ | Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy | Unknown status | European Commission | Phase 2 | 2016-02-01 | This investigator initiated,international, multicenter open-label, randomized controlled trial aims to assess whether a 5 day course of oral nonabsorbable antibiotics (colistin sulfate 2 million IU per os 4x/day and neomycin sulfate 500 mg (salt) per os 4x/day ) followed by fecal microbiota transplantation (administered either via nasogastric administration or via capsules) is effective at eradicating intestinal carriage of beta-lactamase producing Enterobacteriaceae (ESBL-E) and carbapenemase producing Enterobacteriaceae (CPE). compared to no intervention (current standard of care) in adult non-immunosuppressed patients . |
| NCT02472600 ↗ | Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy | Unknown status | Stephen Harbarth | Phase 2 | 2016-02-01 | This investigator initiated,international, multicenter open-label, randomized controlled trial aims to assess whether a 5 day course of oral nonabsorbable antibiotics (colistin sulfate 2 million IU per os 4x/day and neomycin sulfate 500 mg (salt) per os 4x/day ) followed by fecal microbiota transplantation (administered either via nasogastric administration or via capsules) is effective at eradicating intestinal carriage of beta-lactamase producing Enterobacteriaceae (ESBL-E) and carbapenemase producing Enterobacteriaceae (CPE). compared to no intervention (current standard of care) in adult non-immunosuppressed patients . |
| NCT02482961 ↗ | Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection | Completed | DongGuk University | 2015-05-01 | This study purposed to examine the adequate range of therapeutic concentration for Korean people by observing curative effects, side effects, blood concentration, etc. in treating CRAB-infected patients with colistin. | |
| NCT02694393 ↗ | Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis | Active, not recruiting | Cystic Fibrosis Foundation | Phase 1/Phase 2 | 2016-02-01 | This study will assess the safety of inhaled sodium nitrite in adults with Cystic Fibrosis and chronic Pseudomonas infections, and determine the ability of sodium nitrite to reduce the burden of Pseudomonas. |
| NCT02694393 ↗ | Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis | Active, not recruiting | Cystic Fibrosis Foundation Therapeutics | Phase 1/Phase 2 | 2016-02-01 | This study will assess the safety of inhaled sodium nitrite in adults with Cystic Fibrosis and chronic Pseudomonas infections, and determine the ability of sodium nitrite to reduce the burden of Pseudomonas. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for COLISTIN SULFATE
Condition Name
Clinical Trial Locations for COLISTIN SULFATE
Trials by Country
Clinical Trial Progress for COLISTIN SULFATE
Clinical Trial Phase
Clinical Trial Sponsors for COLISTIN SULFATE
Sponsor Name
